Stock Scorer

Artiva Biotherapeutics, Inc. (ARTV)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 10M 20M 30M Q1 '23: 989K Q2 '23: 3.5M Q3 '23: 26.7M Q4 '23: 1.8M Q1 '24: 251K Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q1 '23 Q2 '23 Q3 '23 Q4 '23 Q1 '24 Q2 '24 Q3 '24 Q4 '24

Operating Income Quarterly

-30M -20M -10M 0 10M 20M 30M Q1 '23: -17.7M Q2 '23: -11.8M Q3 '23: 10.8M Q4 '23: -12M Q1 '24: -14.5M Q2 '24: -16.2M Q3 '24: -18.3M Q4 '24: -18.3M Q1 '25: -22.2M Q2 '25: -22.8M Q3 '25: -22.9M Q4 '25: -21.9M Q1 '26: -24.4M Q2 '26: -26.9M Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Net Income Quarterly

-27M -18M -9M 0 9M 18M 27M Q1 '23: -16.7M Q2 '23: -11.3M Q3 '23: 11.3M Q4 '23: -12M Q1 '24: -14M Q2 '24: -17.8M Q3 '24: -17.5M Q4 '24: -16.1M Q1 '25: -20.3M Q2 '25: -21.3M Q3 '25: -21.5M Q4 '25: -20.8M Q1 '26: -23.5M Q2 '26: -25M Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Cash Flow Quarterly

-24M -16M -8M 0 8M 16M 24M Q3 '23: -10.7M Q4 '23: -10.7M Q1 '24: -15.1M Q2 '24: -13.7M Q3 '24: -11.6M Q4 '24: -14.7M Q1 '25: -19.8M Q2 '25: -23M Q3 '25: -19.2M Q4 '25: -14.7M Q1 '26: -20.9M Q2 '26: -20.4M Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Free Cash Flow Quarterly

-27M -18M -9M 0 9M 18M 27M Q3 '23: -10.9M Q4 '23: -11.3M Q1 '24: -15.1M Q2 '24: -14.1M Q3 '24: -11.7M Q4 '24: -14.7M Q1 '25: -20.4M Q2 '25: -24M Q3 '25: -19.8M Q4 '25: -15.1M Q1 '26: -21.2M Q2 '26: -20.8M Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q2 '23: 800.9K Q3 '23: 7M Q1 '24: 809.8K Q2 '24: 811.2K Q3 '24: 18.9M Q1 '25: 24.3M Q2 '25: 24.4M Q3 '25: 24.5M Q1 '26: 24.7M Q2 '26: 39.4M Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-60.00 -40.00 -20.00 0.00 20.00 40.00 60.00 Q4 '23: -35.78 Q1 '24: -44.60 Q2 '24: -52.51 Q3 '24: -55.05 Q4 '24: -5.81 Q1 '25: 10.60 Q2 '25: 31.73 Q3 '25: 31.77 Q4 '25: -3.42 Q1 '26: -3.54 Q2 '26: -3.30 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for ARTV: Gross Profit, Cost of Revenue. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.